GMP-grade neural progenitor derivation and differentiation from clinical-grade human embryonic stem cells

Area of Science:

• Stem Cell Biology
• Neuroscience
• Regenerative Medicine

Background:

• Clinical translation of human pluripotent stem cells requires safe and controlled differentiation protocols.
• Adapting research-grade reagents to Good Manufacturing Practice (GMP) standards is essential but challenging.
• Limited published protocols exist to guide this critical translational step.

Purpose of the Study:

• To adapt existing research protocols for deriving and differentiating long-term neuroepithelial stem cell progenitors (lt-NES) using GMP-grade reagents.
• To establish a robust and reproducible protocol for clinical applications.

Main Methods:

• Adapted research-grade protocols for lt-NES derivation and differentiation to GMP-grade reagents.
• Screened protocol robustness using six clinical-grade human embryonic stem cell (hESC) lines.
• Validated the derivation and differentiation of lt-NES under GMP conditions.

Main Results:

• Successfully derived lt-NES that are multipotent, bankable, and karyotypically stable.
• Demonstrated robust and reproducible differentiation of clinical-grade hESCs into lt-NES.
• Showcased high neurogenic potential and subtype differentiation capacity of GMP-derived lt-NES.

Conclusions:

• Reported the feasibility of deriving and differentiating clinical-grade hESCs into lt-NES under GMP conditions.
• The developed protocol is a flexible tool for accelerating the clinical translation of pluripotent stem cells.
• This work facilitates the development of novel neurological therapies and regenerative medicine strategies.